GlassScriptPhysician profile
Erin Harrell
NPI 1376066688
$3,553.57
in general payments reported to CMS, 2019-2025
24 companies · $875 in 2025
The $875 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $582 · 2023: $590 · 2024: $701 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $365.28 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $344.43 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $333.71 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Amgen INC. | $322.02 | 2021-2023 | Repatha |
| Pfizer INC. | $309.63 | 2021-2025 | |
| Medtronic, INC. | $213.35 | 2024-2025 | Micra, Symplicity G3 |
| Philips North America LLC | $211.83 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Esperion Therapeutics, INC. | $208.55 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $202.55 | 2021-2024 | Xarelto |
| Irhythm Technologies, INC. | $193.41 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $180.38 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.76 | 2021-2025 | Jardiance |
| Scpharmaceuticals INC. | $129.08 | 2024-2025 | |
| Amarin Pharma, INC. | $68.96 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $58.15 | 2023-2024 | Inpefa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $50.38 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $43.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.08 | 2023-2025 | |
| Boston Scientific Corporation | $37.69 | 2022 | |
| Novo Nordisk INC | $35.19 | 2024-2025 | Ozempic, Rybelsus |
| Nuwellis, INC. | $21.18 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.46 | 2022 | |
| Mannkind Corporation | $18.26 | 2025 | |
| Chiesi USA, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.